<DOC>
	<DOC>NCT01471808</DOC>
	<brief_summary>The purpose of this study is to investigate and evaluate the effects of different oral antihyperglycaemic agents combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.metformin and pioglitazone combined with CSII; 3. sitagliptin combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.</brief_summary>
	<brief_title>Effects of Different Early Intensive Therapies on Long-term β-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>newly diagnosed type 2 diabetes fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L body mass index (BMI) ranging from20～35kg/m2 Antihyperglycaemic and antihyperlipidemic medicationnaive patients having any severe acute or chronic diabetic complications renal dysfunction, blood creatinine≥150µmol/L blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT) • Any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months chronic or acute pancreatic disease severe systematic diseases or malignant tumor female patients incline to be pregnant being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>